FOLH1 and neoplasm: During PSMA targeted radioligand therapy using [177Lu]Lu-PSMA-617 more than 30% of patients may not respond to therapy, and the relapse rate remains high, which is partly attributed to poor pharmacokinetics and particularly due to insufficient dose delivery to the tumor (Kratochwil et al. 2016).